Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Leukemia, Promyelocytic, Acute 1Leukemia, Prolymphocytic, T-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Arsenic Trioxide 6Tretinoin 5venetoclax 1arsenous acid 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Idarubicin 1Gemtuzumab 1Gadolinium 1Fluorodeoxyglucose F18 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Promyelocytic, Acute × Lisaftoclax × 1 year × Clear all
NCT07597941 2026-06-04

Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

The Affiliated People's Hospital of Ningbo University

Phase 2/3 Not yet recruiting
60 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡